Literature DB >> 3760981

Recurrent medullary carcinoma of the thyroid demonstrated by thallium-201 scintigraphy.

N B Arnstein, J E Juni, J C Sisson, R V Lloyd, N W Thompson.   

Abstract

Thallium-201 scintigraphy has been used in the evaluation of thyroid neoplasms, but uptake in recurrent or persistent medullary thyroid cancer has not been reported. We present two cases where focal 201TI activity localized superior mediastinal recurrences which were subsequently resected. Postoperative 201TI scans in both cases showed elimination of the focal uptake seen before surgery, as well as return of previously elevated serum calcitonin levels to normal. Scanning with 201TI may be useful in the preoperative localization of recurrent medullary thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3760981

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Accumulation of thallium-201 in medullary thyroid cancer with negative serum calcitonin and carcinoembryonic antigens: a case report.

Authors:  M Koizumi; T Watari; K Hirabayashi
Journal:  Ann Nucl Med       Date:  1993-02       Impact factor: 2.668

2.  Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid.

Authors:  O Ugur; L Kostakğlu; N Güler; B Caner; U Uysal; N Elahi; M Haliloğlu; D Yüksel; T Aras; H Bayhan; C Bekdik
Journal:  Eur J Nucl Med       Date:  1996-10

3.  Scintigraphic detection of recurrence of medullary thyroid cancer.

Authors:  M Koizumi; Y Yamada; E Nomura; M Amano; Y Okajima; H Okizuka; K Yamada; S Sawano; T Kitahara; T Yamashita
Journal:  Ann Nucl Med       Date:  1995-05       Impact factor: 2.668

Review 4.  Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging.

Authors:  Evangelia Skoura
Journal:  Int J Endocrinol Metab       Date:  2013-10-01

5.  Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.

Authors:  P Magnani; G Paganelli; C Songini; A Samuel; F Sudati; A G Siccardi; F Fazio
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.